Comprehensive Real-Time News Feed for Framingham, MA.
Results 1 - 5 of 5 for "u:biospace.com" in Framingham, MA
FRAMINGHAM, Mass. & SYDNEY-- -- SCIEX , a global leader in life science analytical technologies, has announced that Children's Medical Research Institute has opened ProCana , the Australian Cancer Research Foundation International Centre for the Proteome of Human Cancer. Comment?
Alzheon To Present New Clinical Data And Analyses For ALZ-801 And Its Active Molecule Tramiprosate At The 13th International Conference On Alzheimer's And Parkinson's Diseases FRAMINGHAM, Mass., February 13, 2017 - Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders, today announced that the company will be making four presentations at the 13th International Conference on Alzheimer's and Parkinson's Disease in Vienna, Austria, to be held on March 29 - April 2, 2017. Comment?
Alzheon Presents Analyses From Phase III Clinical Studies Showing Largest Clinical Effects Of Tramiprosate, The Active Molecule Of ALZ-801, In APOE4/4 Homozygous Patients With Mild Alzheimer's Disease Results Support 'Precision Medicine' Approach in Alzheimer's Drug Development and Pivotal Study of ALZ-801 in Genetically-Defined Patients with Mild Alzheimer's Disease to Begin in 2017 FRAMINGHAM, Mass.-- --Alzheon, Inc. today presented new analyses of previous Phase 3 data for tramiprosate, an investigational amyloid anti-aggregation agent and the active molecule of prodrug ALZ-801. The new results strengthen Alzheon's precision medicine approach which identifies distinct biological phenotypes in Alzheimer's disease patients. Comment?
Data published in The Journal of the Prevention of Alzheimer's Disease is the first report to associate efficacy of an amyloid-targeted drug with the number of APOE4 alleles Results enable a novel 'precision medicine' approach in Alzheimer's drug development: Pivotal studies of ALZ-801, an oral prodrug of tramiprosate, to target AD patients who are APOE4 carriers will be initiated in 2017 FRAMINGHAM, Mass.-- --Results published today in The Journal of the Prevention of Alzheimer's Disease describe analyses of Phase 3 data for the investigational amyloid-targeted drug, tramiprosate, in patients with Mild to Moderate Alzheimer's disease . Comment?
FRAMINGHAM, Mass. & MANCHESTER, England-- --The University of Manchester opened the multi-million pound Stoller Biomarker Discovery Centre on June 14th 2016. Comment?
- « Previous
- Next »
Copyright © 2017 Topix LLC